Progressive nature of paroxysmal atrial fibrillation - Observations from a 14-year follow-up study

被引:125
作者
Kato, T [1 ]
Yamashita, T [1 ]
Sagara, K [1 ]
Iinuma, H [1 ]
Fu, LT [1 ]
机构
[1] Cardiovasc Inst, Minato Ku, Tokyo 1060032, Japan
关键词
aging; antiarrhythmia agents; fibrillation;
D O I
10.1253/circj.68.568
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Atrial fibrillation (AF) is believed to occur first as paroxysmal, then be gradually perpetuated, and finally become chronic as the end result. However, this presumed clinical course has not been well confirmed. Methods and Results: The clinical course of recurrent paroxysmal AF (PAF) from its onset was examined in 171 patients (mean follow-up period: 14.1 +/- 8.1 years). This study population consisted of patients with no structural heart disease (n = 88), ischemic heart disease (n = 28), dilated or hypertrophic cardiomyopathy (n = 17), valvular heart disease (n = 35) or other cardiac diseases. The mean age at the onset of AF was 58.3 +/- 11.8 years old. During the mean follow-tip period of 14.1 years, PAF eventually developed into its chronic form in 132 patients under conventional antiarrhythmic therapy (77.2%, 5.5% of patients per year). The independent factors for early development into chronic AF were aging (hazard ratio (HR) 1.27 per 10 years, 95% confidence interval (CI) 1.06-1.47), dilated left atrium (HR 1.39 per 10 mm, 95% CI 1.11-1.69), myocardial infarction (HR 2.33, 95% CI 1.13-4.81), and valvular diseases (HR 2.29, 95% CI 1.22-1.30). Conclusions: The present long-term observations definitely and quantitatively revealed the progressive nature of PAF.
引用
收藏
页码:568 / 572
页数:5
相关论文
共 27 条
[1]   PREVENTION OF SYMPTOMATIC RECURRENCES OF PAROXYSMAL ATRIAL-FIBRILLATION IN PATIENTS INITIALLY TOLERATING ANTIARRHYTHMIC THERAPY - A MULTICENTER, DOUBLE-BLIND, CROSSOVER STUDY OF FLECAINIDE AND PLACEBO WITH TRANSTELEPHONIC MONITORING [J].
ANDERSON, JL ;
GILBERT, EM ;
ALPERT, BL ;
HENTHORN, RW ;
WALDO, AL ;
BHANDARI, AK ;
HAWKINSON, RW ;
PRITCHETT, ELC .
CIRCULATION, 1989, 80 (06) :1557-1570
[2]   Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat [J].
Ausma, J ;
Wijffels, M ;
Thone, F ;
Wouters, L ;
Allessie, M ;
Borgers, M .
CIRCULATION, 1997, 96 (09) :3157-3163
[3]   Impact of atrial fibrillation on the risk of death [J].
Benjamin, EJ ;
Wolf, PA ;
D'Agostino, RB ;
Silbershatz, H ;
Kannel, WB ;
Levy, D .
CIRCULATION, 1998, 98 (10) :946-952
[4]   INDEPENDENT RISK-FACTORS FOR ATRIAL-FIBRILLATION IN A POPULATION-BASED COHORT - THE FRAMINGHAM HEART-STUDY [J].
BENJAMIN, EJ ;
LEVY, D ;
VAZIRI, SM ;
DAGOSTINO, RB ;
BELANGER, AJ ;
WOLF, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (11) :840-844
[5]   Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation - The Strategies of Treatment of Atrial Fibrillation (STAF) study [J].
Carlsson, J ;
Miketic, S ;
Windeler, J ;
Cuneo, A ;
Haun, S ;
Micus, S ;
Walter, S ;
Tebbe, U .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (10) :1690-1696
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   Medical progress: Atrial fibrillation. [J].
Falk, RH .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1067-1078
[8]   Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans [J].
Goette, A ;
Arndt, M ;
Röcken, C ;
Spiess, A ;
Staack, T ;
Geller, JC ;
Huth, C ;
Ansorge, S ;
Klein, HU ;
Lendeckel, U .
CIRCULATION, 2000, 101 (23) :2678-2681
[9]   Rhythm or rate control in atrial fibrillation - Pharmacological intervention in atrial fibrillation (PIAF): a randomised trial [J].
Hohnloser, SH ;
Kuck, KH ;
Lilienthal, J .
LANCET, 2000, 356 (9244) :1789-1794
[10]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481